Altamira Therapeutics Ltd (CYTO) - Total Stockholders' Equity
Altamira Therapeutics (CYTO) is undergoing a large-scale business model pivot, replacing outdated ENT products with a polymer RNA delivery system. The asset value tracked on this chart currently stands at 0.00. The company is developing the OligoPhore platform, relying on payments from pharma partners and the sale of its previous nasal developments. Additionally, Altamira Therapeutics is creating inhalation agents for the therapy of pulmonary pathologies and allergies, applying its drug transport methods across various niches.
%20Company%20Book%20Value&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_CYTO_-_Altamira-Therapeutics_-_Company-Book-Value "Auris Medical (CYTO): Net Asset Value from 07/04/2022 to 01/04/2025 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Auris Medical (CYTO)
Book value capitalization reflects the value of the net assets of Altamira Therapeutics (CYTO), excluding market speculation and demonstrating the real financial foundation of the business. An analysis of the current book value capitalization allows for an assessment of the resource base for deploying software robots and automating RNA therapy data analysis, confirming the company's ability to fund high-tech molecule screening without critical dependence on external borrowings.